| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22743 | OSSK-674842 | A novel potent CFTR potentiator that blocks hCFTR with apparent Kd of 71.3 uM. |
|
| DC22739 | OSSK-630513 | A novel potent CFTR potentiator with Kd of 31.7 nM. |
|
| DC21855 | ZINC 39395747 Featured | ZINC 39395747 is a novel potent derivative of propylthiouracil that functions as a cell-active inhibitor of cytochrome b5 reductase 3 (CYB5R3) with IC50 of 9.14 uM. |
|
| DC11600 | D211 | A novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs). |
|
| DC20437 | Linzagolix | A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
|
| DC20482 | Opigolix | A novel potent gonadotrophin releasing hormone (GnRH) antagonist.. |
|
| DC22861 | CRT-0105950 | A novel potent LIMK inhibitor with IC50 of 0.3 nM and 1 nM for LIMK1 and LIMK2, respectively. |
|
| DC22862 | CRT-0105446 | A novel potent LIMK inhibitor with IC50 of 8 nM and 32 nM for LIMK1 and LIMK2, respectively. |
|
| DC11622 | MAP3K14-IN-173 | A novel potent MAP3K14 kinase inhibitor with IC50 of 1.8 nM (NIK autophosphorylation). |
|
| DC11515 | Azeloprazole | A novel potent proton pump inhibitor that irreversibly inhibits H+,K+-ATPase activity with IC50 of 0.28 uM. |
|
| DC23393 | BETi-211 | A novel potent small-molecule BET bromodomain (BRD) inhibitor that binds to BET proteins with Ki values of <1 nM. |
|
| DC11995 | BI 703704 | A novel potent soluble guanylate cyclase (sGC) activator. |
|
| DC11880 | TH1834 | A novel potent specific histone acetyltransferaseTip60 inhibitor. |
|
| DC11881 | TH1834 dihydrochloride | A novel potent specific histone acetyltransferaseTip60 inhibitor. |
|
| DC22798 | ADA-07 | A novel potent TOPK inhibitor that effectively suppresses SUV-induced activation of MAPKs signal transduction resulting in reduced SUV-induced skin carcinogenesis. |
|
| DC11603 | SR-19871 | A novel potent ULK1 inhibitor with IC50 of 11 nM.. |
|
| DC11693 | AJS1669 sodium | A novel potent, allosteric, orally available muscle glycogen synthase 1 (GYS1) activator with EC50 of 5.2 uM. |
|
| DC11692 | AJS1669 | A novel potent, allosteric, orally available muscle glycogen synthase 1 (GYS1) activator with EC50 of 5.2 uM. |
|
| DC21354 | MT47-100 | A novel potent, allosteric, simultaneously direct activator and inhibitor of AMPK complexes containing the β1 or β2 isoform, respectively. |
|
| DC23525 | AAT-008 | A novel potent, and selective prostaglandin EP4 receptor antagonist with binding IC50 of 2.4 nM. |
|
| DC22688 | AZD 3676 | A novel potent, combined serotonin 5-HT1A and 5-HT1B receptor antagonist with Ki of 0.13 and 2.4 nM in brain homogenates, respectively. |
|
| DC11986 | OX03050 | A novel potent, competitive squalene synthase inhibitor that upregulate the LDLR in mouse and human liver cell lines with EC50 of 26 nM. |
|
| DC20692 | ASP 8477 | A novel potent, highly selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 of 0.99, 1.65 and 57.3 nM for human FAAH-1, FAAH-1 (P129T) and FAAH-2, respectively. |
|
| DC21507 | PHA-408 | A novel potent, highly selective, ATP-competitive IKK-2 inhibitor with IC50 of 40 nM, 350-fold selectivity over IKK-1. |
|
| DC23309 | BCL6 inhibitor 8c | A novel potent, in vivo-active BCL6 inhibitor with IC50 of 0.1 uM in ELISA assays. |
|
| DC21209 | KW-2581 | A novel potent, irreversible and orally active inhibitor of steroid sulfatase (STS) with IC50 of 13 nM in ZR-75-1 cells. |
|
| DC11769 | MPO-IN-28 Featured | A novel potent, irreversible Myeloperoxidase (MPO) inhibitor with IC50 of 44 nM. |
|
| DC21058 | GNS-1481 | A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 6.2, 3.4 and 4.2 nM for L858R-T790M, T790M and Del19-T790M, respectively. |
|
| DC21059 | GNS-1486 | A novel potent, irreversible, T790M mutant-selective inhibitor of mutant EGFR with IC50 of 8.3, 4.2 and 4.3 nM for L858R-T790M, T790M and Del19-T790M, respectively. |
|
| DC11612 | KBP-7018 hydrochloride | A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively. |
|
